Developing a vaccine to prevent Entamoeba histolytica infections
Official title: Advanced Development and Clinical Evaluation of an Entamoeba Histolytica Vaccine
Funded at Access to Advanced Health Institute · NIH-11060583 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from a parasite that can cause serious stomach problems, and if it works well, it could be especially helpful for those living in places where these infections are more common.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Access to Advanced Health Institute NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 21, 2018 |
| Project end | November 22, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,260,556 |
| NIH project number | 272201800025C-P00013-9999-1 |
| Project ID | NIH-11060583 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals living in areas with high rates of Entamoeba histolytica infections or those at increased risk due to travel or exposure.
✕Less likely to help
Patients who are not at risk for Entamoeba histolytica infections or those with existing infections may not benefit from this research.
What this research studies
This research focuses on creating and testing a vaccine against Entamoeba histolytica, a parasite that can cause severe gastrointestinal illness. The project involves formulating the vaccine components, conducting stability tests, and evaluating the vaccine's effectiveness and safety in animal models before moving to human trials. Patients may benefit from this vaccine if it proves effective in preventing infections caused by this parasite, especially in areas where such infections are common.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of Entamoeba histolytica infections in at-risk populations.
How similar studies have gone: While vaccines for other infectious diseases have shown success, this specific approach for Entamoeba histolytica is relatively novel and has not been extensively tested.
Where this research is happening
-
Access to Advanced Health Institute
Seattle, United States Active
Researchers
- Principal investigator: Fox, Christopher — Access to Advanced Health Institute
- Study coordinator: Fox, Christopher
Related research
Other NIH-funded projects on the same topics.
-
Developing vaccines for infectious diseases and biodefense
This study is working on developing new vaccines to protect people from infectious diseases that could come from natural outbreaks or intentional releases, and it's testing these vaccines in animals to make sure they're safe and effective before they can be used in humans.
-
Developing vaccines for biodefense and emerging infectious diseases
This study is working on new vaccines to help protect people from serious infections that could come from natural outbreaks or intentional releases, and it aims to make sure these vaccines are safe and effective for everyone.
-
Developing a vaccine to prevent Entamoeba histolytica infections
This study is working on a new nasal vaccine to help protect people from a parasite that causes serious stomach issues, and if it works well in tests, it could offer a new way to prevent these infections in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.